Explore

Trendline Trendline
Eli Lilly's Stock Split Consideration Amid Obesity Drug Success

Eli Lilly's Stock Split Consideration Amid Obesity Drug Success

Eli Lilly's Stock Split Consideration Amid Obesity Drug Success
Reuters Reuters
Eli Lilly raises annual revenue forecast as GLP-1 drugs fuel growth

Eli Lilly raises annual revenue forecast as GLP-1 drugs fuel growth

Aug 5 (Reuters) - Eli Lilly and Co posted better-than-expected quarterly results and raised its full-year revenue forecast on Wednesday, banking on sustained demand for its blockbuster GLP-1 weight-loss and diabetes drugs, sending its shares up 5% in premarket trading.
Reuters Reuters
Eli Lilly to offer early access to next-gen obesity drug to some patients

Eli Lilly to offer early access to next-gen obesity drug to some patients

By Sneha S K and Deena Beasley Aug 3 (Reuters) - Eli Lilly said on Monday it would allow a limited number of patients to have early access to its experimental obesity drug, retatrutide, before its U.S. FDA approval.
Trendline Trendline
Merck Reports Q2 2026 Financial Results Amid Key Product Launches

Merck Reports Q2 2026 Financial Results Amid Key Product Launches

Merck Reports Q2 2026 Financial Results Amid Key Product Launches
Trendline Trendline
Biotech Companies Poised to Surpass Q2 Earnings Expectations Amid Strong Sector Performance

Biotech Companies Poised to Surpass Q2 Earnings Expectations Amid Strong Sector Performance

Biotech Companies Poised to Surpass Q2 Earnings Expectations Amid Strong Sector Performance
Trendline Trendline
CRISPR Therapeutics Outlines Second-Half Pipeline After Strong Q2

CRISPR Therapeutics Outlines Second-Half Pipeline After Strong Q2

CRISPR Therapeutics Outlines Second-Half Pipeline After Strong Q2
Trendline Trendline
Merck Reports Q2 2026 Financial Results, Highlights Key Drug Approvals

Merck Reports Q2 2026 Financial Results, Highlights Key Drug Approvals

Merck Reports Q2 2026 Financial Results, Highlights Key Drug Approvals
Trendline Trendline
Saab Anticipates Increased Production of T-7A Red Hawk Following U.S. Air Force Milestone

Saab Anticipates Increased Production of T-7A Red Hawk Following U.S. Air Force Milestone

Saab Anticipates Increased Production of T-7A Red Hawk Following U.S. Air Force Milestone
Trendline Trendline
Gilead Sciences Reports Strong Revenue Growth Despite Losses in Q2 2026

Gilead Sciences Reports Strong Revenue Growth Despite Losses in Q2 2026

Gilead Sciences Reports Strong Revenue Growth Despite Losses in Q2 2026
Trendline Trendline
Pfizer's Q2 2026 Earnings Highlight COVID's Impact on Revenue Guidance

Pfizer's Q2 2026 Earnings Highlight COVID's Impact on Revenue Guidance

Pfizer's Q2 2026 Earnings Highlight COVID's Impact on Revenue Guidance
Reuters Reuters
Analysis-Obesity battle heats up again as Novo claws way back into race with Lilly

Analysis-Obesity battle heats up again as Novo claws way back into race with Lilly

By Maggie Fick and Bhanvi Satija LONDON, Aug 3 - Novo Nordisk investors have found little cause for optimism during a bruising two-year period of profit warnings, leadership upheaval and a sliding share price as rival Eli Lilly streaked ahead. Now they may have reason for hope.
Reuters Reuters
AstraZeneca investors baulk at $400 billion Bristol Myers talks

AstraZeneca investors baulk at $400 billion Bristol Myers talks

By Maggie Fick LONDON, Aug 3 (Reuters) - AstraZeneca's shares fell sharply on Monday as investors baulked at reports of merger talks with Bristol Myers Squibb about forming what would become one of the world's biggest drugmakers with a combined value of nearly $400 billion.